Laser Interstitial Thermal Therapy for Neurological Conditions

Policy # 00779
Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy is addressed separately in medical policy 00045.

Note: Vagus Nerve Stimulation is addressed separately in medical policy 00134.

Note: Responsive Neurostimulation for the Treatment of Refractory Partial Epilepsy is addressed separately in medical policy 00674.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider laser interstitial thermal therapy (LITT, also known as magnetic resonance-guided laser interstitial thermal therapy or MRgLITT, i.e., NeuroBlate® System or Visualase™ Thermal Therapy System) for treatment of drug-resistant disabling epilepsy to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility for laser interstitial thermal therapy (LITT, also known as magnetic resonance-guided laser interstitial thermal therapy or MRgLITT, i.e., NeuroBlate® System or Visualase™ Thermal Therapy System) for treatment of drug-resistant disabling epilepsy will be considered when ALL of the following criteria are met:

- Evidence of medically refractory and disabling epilepsy with documented failure to respond to at least 2 tolerated antiepileptic drug regimens; AND
- Confirmed well-defined 1-2 epileptogenic foci accessible by MRgLITT; AND
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy #    00779
Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023

- Treatment plan to use LITT as the best treatment option for the patient has been agreed upon
  by a multidisciplinary team of at least 2 specialists, e.g., neurosurgery and neurology.

Note:
Seizures are considered medically refractory when 2 appropriately chosen and used drug schedules
(monotherapies or in combination) failed to achieve sustained seizure freedom. Seizures are
considered disabling when causing impairment or loss of functional status.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or
biological products.

Based on review of available data, the Company considers laser interstitial thermal therapy (LITT)
for drug-resistant disabling epilepsy when coverage criteria are not met, and for all other
neurological indications, including but not limited to patients with primary or metastatic brain
tumors and radiation necrosis to be investigational.*

Background/Overview

Laser Interstitial Thermal Therapy

Laser interstitial thermal therapy (LITT) involves the introduction of a laser fiber probe to deliver
thermal energy for the targeted ablation of diseased tissue. Thermal destruction of tissue is mediated
via DNA damage, necrosis, protein denaturation, membrane dissolution, vessel sclerosis, and
coagulative necrosis. The goal of therapy is selective thermal injury through the maintenance of a
sharp thermal border, as monitored via the parallel use of real-time magnetic resonance (MR)
thermography and controlled with the use of actively cooled applicators. In neurological
applications, LITT involves the creation of a transcranial burr hole for the placement of the laser
probe at the target brain tissue. Probe position, ablation time, and intensity are controlled under MRI
guidance.

The majority of neurological LITT indications described in the literature involve the ablation of
primary and metastatic brain tumors, epileptogenic foci, and radiation necrosis in surgically
inaccessible or eloquent brain areas. LITT may offer a minimally invasive treatment option for
patients with a high risk of morbidity with traditional surgical approaches. The most common
complications following LITT are transient and permanent weakness, cerebral edema, hemorrhage, seizures, and hyponatremia. Delayed neurological deficits due to brain edema are temporary and typically resolve after corticosteroid therapy. Contraindications to magnetic resonance imaging (MRI) are also applicable to the administration of LITT.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

In August 2007, the Visualase™ MRI-Guided Laser Ablation System (Medtronic; formerly Biotex, Inc.) received initial marketing clearance by the U.S. Food and Drug Administration (FDA) through the 510(k) pathway (K071328). In January 2022 (K211269), the system (software version 3.4) was classified as a neurosurgical tool with narrowed indications for use, including "to ablate, necrotize or coagulate intracranial soft tissue including brain structures (for example, brain tumor, radiation necrosis and epileptic foci as identified by non-invasive and invasive neurodiagnostic testing, including imaging) through interstitial irradiation or thermal therapy in medicine and surgery in the discipline of neurosurgery with 800 nm through 1064 nm lasers." The device is contraindicated for patients with medical conditions or implanted medical devices contraindicated for MRI and for patients whose physician determines that LITT or invasive surgical procedures in the brain are not acceptable. Data from compatible MRI sequences can be processed to relate imaging changes to relative changes in tissue temperature during therapy. The Visualase™ cooling applicator utilizes saline.

In April 2013, the NeuroBlate® System (Monteris Medical) received initial clearance for marketing by the FDA through the 510(k) pathway (K120561). As of August 2020, the system is indicated for use “to ablate, necrotize, or coagulate intracranial soft tissue, including brain structures (eg, brain tumor and epileptic foci as identified by non-invasive and invasive neurodiagnostic testing, including imaging), through interstitial irradiation or thermal therapy in medicine and surgery in the discipline of neurosurgery with 1064 nm lasers” (K201056). The device is intended for planning and monitoring of thermal therapy under MRI guidance, providing real-time thermographic analysis of selected MRI images. The NeuroBlate® system utilizes a laser probe with a sapphire capsule to promote prolonged, pulsed laser firing and a controlled cooling applicator employing pressurized CO₂.
On April 25, 2018, the FDA issued a safety alert on MR-guided LITT (MRgLITT) devices with a letter to healthcare providers stating that the FDA is currently evaluating data suggesting that potentially inaccurate MR thermometry information can be displayed during treatment, which may contribute to a risk of tissue overheating and potentially associated adverse events, including neurological deficits, increased intracerebral edema or pressure, intracranial bleeding, and/or visual changes. Several risk mitigation strategies were recommended. In an updated letter released on November 8, 2018, risk mitigation recommendations specific to the Visualase™ and NeuroBlate® systems were issued.

**Rationale/Source**
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Laser interstitial thermal therapy (LITT) involves the introduction of a laser fiber probe to deliver thermal energy for the targeted ablation of diseased tissue. The goal of therapy is selective thermal injury through the maintenance of a sharp thermal border, as monitored via the parallel use of real-time magnetic resonance (MR) thermography and controlled with the use of actively cooled applicators. In neurological applications, LITT involves the creation of a transcranial burr hole for the placement of the laser probe at the target brain tissue. Probe position, ablation time, and intensity are controlled under magnetic resonance imaging (MRI) guidance. LITT has been proposed as a less invasive treatment option for patients with neurological conditions compared to surgery. Two LITT systems, Visualase and NeuroBlate, have received marketing clearance from the U.S. Food and Drug Administration (FDA).

**Summary of Evidence**
For individuals who have primary or metastatic brain tumors who receive MR-guided LITT, the evidence includes systematic reviews and meta-analyses and several nonrandomized comparative and single-arm studies. Relevant outcomes are overall survival (OS), disease-specific survival, symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Overall survival estimates have ranged from 9.0 to 14.4 months in new or recurrent
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy #  00779  
Original Effective Date:  04/11/2022  
Current Effective Date:  04/10/2023

glioblastoma. Among patients with metastatic tumors receiving LITT following prior SRS, OS rates have ranged between 72% to 76% at 6 months and 63% to 65% at 12 months. Systematic reviews comparing LITT to open craniotomy with resection or stereotactic radiosurgery (SRS) suggest a reduced incidence of adverse events with LITT; however, neurological deficits attributable to LITT-induced thermal damage have been observed despite concurrent MRI guidance. Studies are limited by predominantly retrospective designs, small sample sizes, and population heterogeneity, with study subjects varying by performance status, lesion volume and location, extent of prior therapies, and extent of ablation. Prospective comparative studies in well-defined and -controlled patient populations are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic cranial radiation necrosis who receive MR-guided LITT, the evidence includes meta-analyses, 3 nonrandomized comparative studies, and 1 single-arm study. Relevant outcomes are OS, disease-specific survival, symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Studies have reported improved local control and survival outcomes in patients with radiation necrosis compared to those with brain metastases. One study comparing LITT to bevacizumab suggested that LITT treatment may be more successful among patients before radiation necrosis lesions become symptomatic. One study comparing LITT to craniotomy and one study comparing LITT to medical management did not report significant survival differences between groups. Studies are limited by retrospective designs, small sample sizes, population heterogeneity, and unclear relevance, as symptomatic status and steroid-related morbidity were not consistently reported. Prospective comparative studies in well-defined and -controlled patient populations are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have drug-resistant epilepsy who receive MR-guided LITT, the evidence includes systematic reviews and meta-analyses, 2 nonrandomized comparative studies, and 3 single-arm studies. Relevant outcomes are disease-specific survival, symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Meta-analyses have reported seizure freedom rates ranging from 50% to 61% but are limited by heterogeneous study populations and follow-up durations. Studies comparing LITT to open resection have reported comparable outcomes in patients with pediatric insular epilepsy and adult temporal lobe epilepsy (TLE). In one meta-analysis comparing LITT to radiofrequency ablation (RFA) and conventional surgery, superior outcomes were noted with conventional surgery among patients with mesial TLE (mTLE). A
subsequent meta-analysis concluded that while there is no evidence to suggest that LITT is less effective than open surgical resection in the short term, long-term data are lacking. Total quality of life scores reported in the ongoing LAANTERN registry increased by 72.4%, but this change was not considered statistically significant. Prospective comparative studies in well-defined and controlled patient populations are required to assess a net health outcome and to identify patients most likely to benefit from LITT.

**Supplemental Information**

**Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

**American Association of Neurological Surgeons et al**

In September 2021, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Joint Section on Tumors issued a position statement regarding the use of laser interstitial thermal therapy (LITT) for brain tumors and radiation necrosis. The statement concludes that "LITT is an appealing option because it offers a method of minimally invasive, targeted thermal ablation of a lesion with minimal damage to healthy tissue. There is a growing body of evidence to demonstrate that LITT is an effective and well tolerated cytoreductive option for treatment of [newly diagnosed glioblastoma multiforme (GBM), recurrent GBM, and primary or recurrent brain metastases.] Intracranial LITT is also an effective option for addressing radiation necrosis with an overall reduction in steroid dependence for these patients. Especially in instances where the therapeutic window is narrowed such that craniotomy is not a viable option, LITT can play an important role in treatment for glioma or metastatic brain cancer."

**American Society of Clinical Oncology et al**

In 2021, the American Society of Clinical Oncology (ASCO) issued a joint evidence-based guideline on the treatment of brain metastases with the Society for Neuro-Oncology (SNO) and the American Society for Radiation Oncology (ASTRO). The guideline stated that "no recommendation can be..."
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy #  00779
Original Effective Date:  04/11/2022
Current Effective Date:  04/10/2023

made for or against laser interstitial thermal therapy (Type: informal consensus; Evidence quality: low; Strength of recommendation: none)."

American Society for Radiation Oncology
The ASTRO clinical practice guideline on radiotherapeutic and surgical management for newly diagnosed brain metastases (2012) does not address the use of LITT.

American Society for Stereotactic and Functional Neurosurgery
In September 2021, the American Society for Stereotactic and Functional Neurosurgery (ASSFN) issued a position statement on the use of LITT in drug-resistant epilepsy. The statement recommends consideration of MR-guided LITT (MRgLITT) as a treatment option when all of the following criteria are met:

- "Failure to respond to, or intolerance of, at least 2 appropriately chosen medications at appropriate doses for disabling, localization-related epilepsy AND
- Well-defined epileptogenic foci or critical pathways of seizure propagation accessible by MRgLITT."

Congress of Neurological Surgeons
The Congress of Neurological Surgeons (CNS) guidelines for the treatment of adults with metastatic brain tumors (2019) state that "there is insufficient evidence to make a recommendation regarding the routine use of laser interstitial thermal therapy (LITT), aside from use as part of approved clinical trials."

National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) clinical practice guidelines for central nervous system cancers (v.2.2022) states that magnetic resonance (MR) -guided LITT "may be considered for patients who are poor surgical candidates (craniotomy or resection). Potential indications include relapsed brain metastases, radiation necrosis, and recurrent glioblastoma." (Category 2B): The guidelines additionally state that LITT "can be considered on a case-by-case basis for treatment of radiation necrosis in patients with a history of radiation therapy for primary brain tumor or metastatic disease. Consultation with adept neurosurgeons trained in LITT should be done when the procedure is considered."
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy #  00779
Original Effective Date:  04/11/2022
Current Effective Date:  04/10/2023

National Institute for Health and Care Excellence
In 2020, NICE published an interventional procedures guidance on the use of MR-guided LITT for drug-resistant epilepsy. The NICE recommends that LITT should only be used with special arrangements, given serious but well-recognized safety concerns and low quality evidence for efficacy.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
In 1997, the Centers for Medicare and Medicaid Services (CMS) issued a national coverage determination on the use of laser procedures, stating that "in the absence of a specific noncoverage instruction, and where a laser has been approved for marketing by the Food and Drug Administration, Medicare Administrative Contractor discretion may be used to determine whether a procedure performed with a laser is reasonable and necessary, and, therefore, covered."

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02970448</td>
<td>Expedited Laser Interstitial Thermal Therapy and Chemoradiation for Patients With Newly Diagnosed High Grade Gliomas</td>
<td>45</td>
<td>Dec 2023 (recruiting)</td>
</tr>
<tr>
<td>NCT02844465a</td>
<td>Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE)</td>
<td>150</td>
<td>Dec 2025 (recruiting)</td>
</tr>
<tr>
<td>NCT04181684</td>
<td>Pilot Study of Laser Interstitial Thermal Therapy Followed By Hypofractionated</td>
<td>32</td>
<td>Feb 2023 (recruiting)</td>
</tr>
</tbody>
</table>
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy # 00779  
Original Effective Date: 04/11/2022  
Current Effective Date: 04/10/2023

<table>
<thead>
<tr>
<th>NCT number</th>
<th>Study Title</th>
<th>NCTID</th>
<th>Enrollment</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT05075850(^a)</td>
<td>Radiation Therapy for Treatment of Recurrent Gliomas (GCC 19140)</td>
<td>250</td>
<td>Jun 2023</td>
<td>recruiting</td>
</tr>
<tr>
<td>NCT04187872(^a)</td>
<td>Patient Neuropsychological Outcomes After Laser Ablation (PENSAR)</td>
<td>16</td>
<td>Oct 2025</td>
<td>recruiting</td>
</tr>
<tr>
<td>NCT04699773</td>
<td>Recurrent Brain Metastasis Immune Effects and Response to Laser Interstitial Thermotherapy (LITT) and Pembrolizumab in Combination (TORCH)</td>
<td>32</td>
<td>Dec 2025</td>
<td>recruiting</td>
</tr>
<tr>
<td>NCT05124912(^a)</td>
<td>Laser Interstitial Thermal Therapy Followed By Hypofractionated Radiation Therapy For Treatment Of Newly Diagnosed High-Grade Gliomas (GCC 20138)</td>
<td>154</td>
<td>Jul 2026</td>
<td>recruiting</td>
</tr>
<tr>
<td>NCT02392078(^a)</td>
<td>REMASTer: REcurrent Brain Metastases After SRS Trial</td>
<td>3000</td>
<td>Dec 2035</td>
<td>recruiting</td>
</tr>
<tr>
<td>NCT04596930</td>
<td>Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry</td>
<td>15</td>
<td>May 2022</td>
<td>completed</td>
</tr>
<tr>
<td>NCT02389855(^a)</td>
<td>MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Randomized Pilot Study (EMITT)</td>
<td>15</td>
<td>Aug 2016</td>
<td>completed</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
\(^a\) Denotes industry-sponsored or cosponsored trial.
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy # 00779
Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023

References
8. Barnett GH, Voigt JD, Alhuwalia MS. A Systematic Review and Meta-Analysis of Studies Examining the Use of Brain Laser Interstitial Thermal Therapy versus Craniotomy for the Treatment of High-Grade Tumors in or near Areas of Eloquence: An Examination of the Extent of Resection and Major Complication Rates Associated with Each Type of Surgery. Stereotact Funct Neurosurg. 2016; 94(3): 164-73. PMID 27322392
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy # 00779
Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023

Laser Interstitial Thermal Therapy for Neurological Conditions

Policy # 00779
Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy #     00779
Original Effective Date:  04/11/2022
Current Effective Date:  04/10/2023

Laser Interstitial Thermal Therapy for Neurological Conditions

Policy # 00779
Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023


Policy History

Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023
03/03/2022 Medical Policy Committee review
03/09/2022 Medical Policy Implementation Committee approval. New policy.
03/02/2023 Medical Policy Committee review
03/08/2023 Medical Policy Implementation Committee approval. Added a “When Services May Be Eligible for Coverage” section for laser interstitial thermal therapy for drug-resistant disabling epilepsy. Revised the investigational statement to reflect the added eligible for coverage section.

Next Scheduled Review Date: 03/2024

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT.
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy #  00779  
Original Effective Date:  04/11/2022  
Current Effective Date:  04/10/2023  

and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>61736, 61737</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Laser Interstitial Thermal Therapy for Neurological Conditions

Policy # 00779
Original Effective Date: 04/11/2022
Current Effective Date: 04/10/2023

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.